25.06.05 (¸ñ) 02:20

Dailypharm

X
"³ëº§»ó°ú L-¾Æ¸£±â´ÑÀÇ ÀÓ»óÀû °¡Ä¡"
µ¥Àϸ®ÆÊ 2017-11-29 12:14:54
"³ëº§»ó°ú L-¾Æ¸£±â´ÑÀÇ ÀÓ»óÀû °¡Ä¡"
µ¥Àϸ®ÆÊ 2017-11-29 12:14:54
ÀǾàǰ ¼ººÐ ¸®ºä | ȲÀº°æ ¾à»ç(ºÎ»ê ¿À°Å¸®¾à±¹)



L-¾Æ½ºÆÄ¸£Æ®»ê-L-¾Æ¸£±â´Ñ°ú ³ëº§»óÀº ¾î¶² »ó°ü°ü°è°¡ ÀÖÀ»±î? ÃÖ±Ù ÀÌ °°Àº ¼ººÐÀ» ÇÔÀ¯ÇÑ ÀϹÝÀǾàǰ, ¶ó¶ó¿Ã¶ó¶ó´Â Á¦Ç°ÀÌ ¾à±¹ Áø¿­´ë¿¡ ¿Ã¶ú´Ù.

1998³â ·Î¹öÆ® F ÆÛÄ¡°íÆ®¿Í ·çÀ̽º À̱׳ª·Î¿Í Æä¸®µå ¹Â¶óµå°¡ ³ëº§ »ý¸®ÇлóÀ» °øµ¿ ¼ö»óÇß´Ù. ½ÉÇ÷°ü°è ½ÅÈ£Àü´Þ ºÐÀÚ·Î NO (nitric oxide, »êÈ­Áú¼Ò)¸¦ ¹ß°ßÇÑ °ø·Î¸¦ ÀÎ Á¤ ¹ÞÀº °ÍÀÌ´Ù. 20³â¼¼¿ù À̵éÀº Ç÷°ü±ÙÀ°¼¼Æ÷¸¦ À̿ϽÃŰ´Â Ç÷°ü³»ÇǼ¼Æ÷¿¡¼­ »ý¼ºµÇ´Â Ç÷°üÀ̿ϿäÀÎ (Endothelium-derived relaxing factor, EDRF)À» ¹ß°ßÇß°í, ÀÌ EDRF°¡ ±âüÀÎ "NO"À̸ç ÀÎü¿¡¼­ È£¸£¸óÀÌ ¾Æ´Ñ ±âü°¡ ½ÅÈ£ Àü´Þ ¹°Áú·Î ÀÛ¿ëÇÏ´Â »õ ¿ø¸®¸¦ ¹àÇô³»¾ú´Ù.

¹Â¶óµå´Â ´ÏÆ®·Î±Û¸®¼¼¸°¿¡¼­ À¯¸®µÈ NO°¡ ¼¼Æ÷Áú ³» guanylate cyclase¸¦ Ȱ¼ºÈ­½ÃÄÑ cGMP³óµµ¸¦ Áõ°¡½ÃŰ°í ½ÉÀå Ç÷°ü ÆòȰ±ÙÀ» À̿ϽÃÄÑ Çù½ÉÁõ¿¡ Àû¿ëÇÒ ¼ö ÀÖ´Ù´Â »ç½ÇÀ» , ÆÛÄ¡ÄÚÆ®´Â Ç÷°ü³»ÇǼ¼Æ÷ÀÇ ±â´ÉÀÌ »ì¾Æ ÀÖ´Â °æ¿ì ¾Æ¼¼Ä¥Äݸ° µî¿¡ ÀÇÇØ EDRF°¡ »ý¼ºµÇ¸é Ç÷°ü ÆòȰ±ÙÀÌ À̿ϵȴٴ »ç½ÇÀ», À̱׳ª·Î´Â EDRF¸¦ ÀÛµ¿½ÃŰ´Â ¹°ÁúÀÌ Ã¼³»¿¡¼­ »ý¼ºµÇ´Â NOÀÓÀ» ¹àÇû´Ù.

NO´Â ȦÀüÀÚÀÇ ÀÚÀ¯¶óµðÄ®À» °¡Áö°í ÀÖ¾î ¹ÝÀÀ¼ºÀÌ ÀÖÀ¸¸ç ¹°¿¡ ¾à°£ ³ìÀ¸¹Ç·Î Á¶Á÷À¸·Î ºü¸£°Ô È®»êµÇ¾î ¿©·¯ °¡Áö ´Ù¾çÇÑ ¿ªÇÒÀ» ¼öÇàÇÒ ¼ö ÀÖ´Ù.

 ¡ã [±×¸² 1] Ç÷°ü³»ÇǼ¼Æ÷¿¡¼­ÀÇ NO »ý¼º°ú Ç÷°ü ÆòȰ±Ù ÀÌ¿Ï [A]
ÀÌÈÄ À̱׳ª·Î´Â NO °¡½º¸¦ ¸¶½Ã±âº¸´Ù ¾Æ¸£±â´Ñ °æ±¸ ¼·Ã븦 ÅëÇØ ü³» NO»ý¼ºÀ» µ½´Â °ÍÀÌ °Ç°­À» À¯ÁöÇÏ´Â ±æÀ̶ó´Â ³»¿ëÀÇ °­¿¬À» Çѱ¹¿¡¼­µµ µÎ Â÷·Ê ÇÑ ÀûÀÌ ÀÖ´Ù.[B]

[±×¸² 2]¿¡¼­ º¸µíÀÌ NO´Â ÇØµ¶À» À§ÇÑ °£ÀÇ urea cycle¿¡¼­µµ »ý¼ºÀÌ µÈ´Ù. ÀÌ urea cycleÀÌ ¿øÈ°È÷ µ¹¾Æ°¡±â À§Çؼ­´Â ¾Æ¸£±â´Ñ°ú ÇÔ²² ¾Æ½ºÆÄ¸£Æ®»êµµ ÇÊ¿äÇÏ´Ù. ÀÌ ¾Æ½ºÆÄ¸£Æ®»êÀº ¿¡³ÊÁö¸¦ »ý¼ºÇÏ´Â crebsȸ·ÎÀÇ Çʼö ¹°ÁúÀ̱⵵ Çѵ¥ urea cycleÀ» ÅëÇÑ ¾Ï¸ð´Ï¾ÆÀÇ Á¦°Å, ÇǷο¡ ´ëÇÑ ÀúÇ×¼º Áõ°¡, Áö±¸·Â Áõ°¡¸¦ À§ÇØ ¾²ÀδÙ. purineÀÇ Àü±¸Ã¼·Î¼­ ÇÙ»ê ÇÕ¼º¿¡ ¾²À̱⵵ ÇÑ´Ù.

 ¡ã [±×¸² 2] urea cycle and krebs cycle [C]

[±×¸² 1]ÀÇ eNOSó·³ NO¸¦ »ý¼ºÇϱâ À§Çؼ­´Â NOS¶ó´Â È¿¼Ò°¡ ÇÊ¿äÇѵ¥ 3°¡ÁöÀÇ ¼­ºêÇüŰ¡ ÀÖ¾î °¢±â ´Ù¸¥ ¿ªÇÒÀ» ÇÑ´Ù. eNOS(endothelial NOS)¿Í nNOS(neuronal NOS), ºÐºñ °¡´ÉÇÑ ÇüÅÂÀÇ iNOS(¸é¿ª¹ÝÀÀ¿¡ ¿¬°ü, Ä®¸ðµÑ¸° °áÇÕÀ¸·Î ¸¹Àº ¾çÀÇ NO¸¦ »ý¼ºÇÏ¿© ¸é¿ª ´ã´ç)°¡ ÀÖ´Ù. ÀÌ eNOS, nNOS, iNOS´Â óÀ½¿¡ °¢°¢ Ç÷°ü³»ÇǼ¼Æ÷, ½Å°æ¼¼Æ÷, ´ë½Ä¼¼Æ÷¿¡¼­ ¹ß°ßµÇ¾úÁö¸¸ ½ÇÁ¦·Î´Â ´Ù¾çÇÑ ¼¼Æ÷³ª Á¶Á÷¿¡ ºÐÆ÷µÇ¾î ÀÖ´Ù.[D]

¸é¿ª°è(iNOS ÀÛ¿ë)¿¡¼­´Â Ç×¾Ï ¹× Ç׹̻ý¹° ÀÛ¿ë, ½Å°æ°è(nNOS ÀÛ¿ë)¿¡¼­´Â ½Å°æÀü´Þ¹°Áú, ¼øÈ¯±â°è(eNOS ÀÛ¿ë)¿¡¼­´Â Ç÷°üÈ®Àå¹°Áú·Î ÀÌÇØÇÏ¸é µÇ´Âµ¥ Ç÷°üÀúÇ×(Áï, Ç÷¾Ð)À» Á¶ÀýÇϰí, Àν¶¸°ºÐºñ, ±âµµÀúÇ×, ¿¬µ¿¿îµ¿, ±×¸®°í Ç÷°ü»ý¼º°ú ½Å°æ°èÀÇ ¹ß»ý, ±â¾ï µî¿¡ °ü¿©ÇÑ´Ù.

[NOÀÇ ¿ªÇÒ]

Á» ´õ Á¤È®È÷ ¾à±¹¿¡¼­ ¾Æ¸£±â´ÑÀ» Åõ¿©Çϱâ À§ÇØ ÇÊ¿äÇÑ ¿Ü±¹ ¹®Çå ¸î ÆíÀ» ¼Ò°³ÇÑ´Ù.

1. Ç÷°ü³»ÇǼ¼Æ÷ÀÇ ±â´ÉÀÌ Á¤»óÀÎ °æ¿ì [E] NO »ý¼ºÀÇ À¯ÀÏÇÑ ±âÁúÀÎ ¾Æ¸£±â´Ñ ¼·Ãë·Î Ç÷°ü ½ÉÀå°èÀÇ Ç×»ó¼ºÀÌ À¯ÁöµÇ¾ú°í µ¿¹°½ÇÇè¿¡¼­ Ç÷¼ÒÆÇ°ú Ç÷¾×ÀÀ°í ½Ã½ºÅÛ¿¡ ¿µÇâÀ» ÁÖ¾ú´Ù.


2. ¾Æ¸£±â´Ñ Åõ¿©´Â[F] °ú´ÙÇÑ È°¼º»ê¼Ò ¾ïÁ¦·Î I/R injury (±¹¼ÒºóÇ÷/Àç°ü·ù¼Õ»ó)¿¹¹æ È¿°ú°¡ ÀÖ´Ù.

3. ¿îµ¿¼±¼ö¿¡°Ô Áö¼ÓÀûÀ¸·Î L-arginine-L- aspartate¸¦ Åõ¿©Çϸé Áö¹æ»ê »êÈ­¸¦ ÃËÁøÇϰí Á¥»êÃàÀûÀ» ÁÙÀ̸ç ÃÑ»ê¼Ò ¼Òºñ¸¦ °¨¼Ò½ÃŰ°í ¿îµ¿ È¿À²À» ³ôÀδÙ.[G]

4. ¿îµ¿Áß ¾Æ¸£±â´Ñ °ø±ÞÀº[H] ±ÙÀ°ÀÇ Æ÷µµ´ç ÀÌ¿ëÀ» Áõ°¡½Ã۰í Áö¹æ»êÀÇ »êÈ­¸¦ ÃËÁø½ÃŲ´Ù.

5. Àå±â°£ÀÇ ¾Æ¸£±â´Ñ ¼·Ãë´Â[I] Á÷°æÀÌ ÀÛÀº °ü»óµ¿¸Æ ³»ÇǼ¼Æ÷ ±â´ÉÀ» Çâ»ó½ÃŲ´Ù.

6. °í¿ë·®ÀÇ ¾Æ¸£±â´Ñ °æ±¸Åõ¿©´Â[J] ¹ß±âºÎÀü¿¡ È¿°ú°¡ ÀÖ´Ù. 60³â´ëºÎÅÍ À¯·´¿¡¼­´Â ³²¼º ºÒÀÓ, ¹ß±âºÎÀü¿¡ ´ëÇÑ ¾Æ¸£±â´Ñ °ü·Ã ¿¬±¸°¡ Áö¼ÓµÇ¾î ¿Ô´Ù.

±¹³» ¹®Çåµµ »êÈ­Áú¼Ò¸¦ Ű¿öµå·Î È®ÀÎÇØº¸¸é Á¤¸» ´Ù¾çÇÑ ¿ëµµ·Î ÀÌ¿ëµÇ´Â °ÍÀ» ¾Ë ¼ö ÀÖ´Ù. ¾Æ¸£±â´Ñ ÇÑ °¡Áö º¹¿ëÀ¸·Î 3°¡ÁöÀÇ ¿ªÇÒÀ» ÇÒ ¼ö Àֱ⠶§¹®ÀÌ´Ù.

Ãâó¿Í °¢ÁÖ
[A] page 501"; name_="Myocardial Oxygen Supply and Demand Relationship: Zipes: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine"

[B] [»ç¶÷»ç¶÷] ³ëº§ ÀÇÇлó ¹ÞÀº ·çÀ̽º À̱׳ª·Î ±³¼ö Áß¾ÓÀϺ¸ 2004.11.21

[C} NMR metabolic profiling of serum identifies amino acid disturbances in chronic fatigue syndrome Christopher W. Armstrong ¿Ü5ÀÎ, Clinica Chimica Acta 413 (2012) 1525–.1531

[D] Synthesis of Nitric Oxide¿¡¼­ ¹ßÃé http://www.reading.ac.uk/nitricoxide/intro/no/synthesis.htm

[E] L-arginine and cardiovascular system

[F] L-Arginine Treatment Alters the Kinetics of Nitric Oxide and Superoxide Release and Reduces Ischemia/Reperfusion Injury in Skeletal Muscle

[G} THE PROLONGED INTAKE OF L-ARGININE-L-ASPARTATE REDUCES BLOOD LACTATE ACCUMULATION AND OXYGEN CONSUMPTION DURING SUBMAXIMAL EXERCISE

[H] L-Arginine infusion increases glucose clearance during prolonged exercise in humans

[I} Long-term L-Arginine Supplementation Improves Small-Vessel Coronary Endothelial Function in Humans

[K] Effect of oral administration of high-dose nitric oxide donor l-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study
µ¥Àϸ®ÆÊ (dailypharm@dailypharm.com) ±âÀÚÀÇ ´Ù¸¥±â»ç º¸±â
  • Àμâ
  • īī¿ÀÅå
  • ÆäÀ̽ººÏ
  • Æ®À§ÅÍ
  • 0
¾à±¹ ÀÏ¹Ý¾à ¸ÅÃâ¾× Top 100(06¿ù)
¼øÀ§ »óǰ¸í Ƚ¼ö
1 ¸®Áêºñ³Ø½ºÅ©¸² 1417
2 ŸÀÌ·¹³îÁ¤500mg(10Á¤) 25792
3 ±î½ºÈ°¸í¼öÅ¥¾× 12046
4 ÄÉÅäÅéÇöó½ºÅ¸(40¸Å) 4883
5 ÆÇÄÝ¿¡½º³»º¹¾× 12330
6 ¾Æ·Î³ª¹Î°ñµåÇÁ¸®¹Ì¾öÁ¤(120Á¤) 1336
7 ÆÇÇǸ°Å¥¾× 9334
8 ¾ÖÅ©³íÅ©¸² 4913
9 ³ë½ºÄ«³ª°Ö 20g 2632
10 º¥Æ÷º§S¿¡½ºÁ¤ 826
11 ÅÙÅÙÃòÁ¤(120Á¤) 1663
12 ºñÆÇÅÙ¿¬°í 30g 3360
13 ¸Æ½ºÄܵå·ÎÀÌÆ¾1200 343
14 ŸÀÌ·¹³îÁ¤500mg(30Á¤) 4449
15 ¾ÖÅ©¸°°Ö 3319
16 ÀÕÄ¡ÆäÀ̽ºÆ®Ä¡¾à120g 3012
17 ¸á¶óÅä´×Å©¸² 1777
18 Áö¸£ÅØÁ¤ 5984
19 ʼ¾ ¿¬Áúĸ½¶(10ĸ½¶) 9709
20 ÄÝ´ë¿ø ÄÚÇÁÅ¥½Ã·´ 7571
21 ÅÙÅÙÃòÁ¤(10Á¤) 11252
22 À̰¡Åº¿¡ÇÁĸ½¶(60ĸ½¶*3) 1159
23 º£³ªÄ¡¿À¿¡ÇÁ¾×75ml 7328
24 µÑÄÚ¶ô½º-¿¡½ºÀå¿ëÁ¤(40Á¤) 1871
25 ±¤µ¿°æ¿Á°í 262
26 ½Å½ÅÆÄ½º¾Æ·º½º ´ëÇü 3835
27 ÈĽõò¿¬°í10g 3520
28 °Ôº¸¸°Á¤(10Á¤) 5190
29 ¾Æ·Î³ª¹Î°ñµåÁ¤(100Á¤) 850
30 µ¿¾ÆD-ÆÇÅ׳°í 2654
31 ʼ¾ ¿¬Áúĸ½¶(30ĸ½¶) 3060
32 ÄÉÆèÇöó½ºÅ¸ 3994
33 ÀÌÁö¿£6À̺꿬Áúĸ½¶(30ĸ½¶) 3008
34 ¿ÀÅ¥½Ã½ºÁ¡¾È¾×0.5ml*60°³ 1409
35 ±¤µ¿¿ìȲû½É¿øÇöʾ×50ml(¿µ¹¦Çâ) 1504
36 ±¤µ¿¿ìȲû½É¿øÇöʾ×50ml(»çÇâ,º¯¹æ) 1014
37 ±¤µ¿¿ìȲû½É¿øÈ¯(»çÇâ) 271
38 ÀÕÄ¡ÆäÀ̽ºÆ®ÇÇſġµå150g 1438
39 ¸¶µ¥Ä«¼ÖÄɾ°í10g 3083
40 ÈĽõò¿¬°í5g 4114
41 ÄÝ´ë¿ø ³ëÁîÅ¥¿¡½º½Ã·´ 5080
42 À¯ÇѺñŸ¹ÎCÁ¤1000mg 1268
43 ±¤µ¿¿øÅÁ 5705
44 ³ë½ºÄ«³ª°Ö10g 1773
45 ÇÁ·»Áî¾ÆÀ̵å·ÓÁ¡¾È¾×ÄðÇÏÀÌ ¾÷ 3440
46 Àλ絹Ç÷¯½º(100Á¤) 625
47 ÇÁ·»Áî¾ÆÀ̵å·ÓÁ¡¾È¾×Äð ¾÷ 3391
48 ÄÝ´ë¿øÄݵåÅ¥½Ã·´ 4547
49 Å×¶óÇÃ·ç ³ªÀÌÆ®Å¸ÀÓ 2291
50 Åõ¿¢½ººñÆ®¸®ÇÃÁ¤ 318
51 ¸®¾ÈÁ¡¾È¾× 903
52 ¸ðµåÄÝ¿¡½º¿¬Áúĸ½¶(10ĸ½¶) 5000
53 ¸Ó½Ã·ÐÁ¤ 1764
54 ÇÁ·»Áî¾ÆÀ̵å·ÓÁ¡¾È¾×¼ø ¾÷ 3103
55 ºñ¸Æ½º¸ÞŸºñÁ¤ 349
56 ¹éÃʽ÷´Ç÷¯½º 2860
57 ÄÚ¸ÞŰ³ªÄ¸½¶ 3559
58 ½Å½ÅÆÄ½º¾Æ·º½º ÁßÇü 3733
59 ¿ÀÆ®¸®ºó¸àÅç0.1%ºÐ¹«Á¦ 1462
60 ŸÀÌ·¹³îÄݵ忡½ºÁ¤ 4070
61 ÄÚ¾ØÄ𠳪Àß½ºÇÁ·¹ÀÌ 1659
62 ¾ÈƼǪ¶ó¹Î ´õºíÆÄ¿ö ´ëÇü 2302
63 ÀÕÄ¡ ÇÁ·ÎÆú¸®½º 1068
64 ¸ÞÀÌŲťÀå¿ëÁ¤(40Á¤) 1452
65 Å×¶óÇ÷ç Äݵå&ÄÚÇÁ ³ªÀÌÆ® 1377
66 ¿ëÇ¥¿ìȲû½É¿ø¾× 50ml(¹«½ºÄÜ,º¯¹æ) 1247
67 °ÖÆ÷½º¿¤Çöʾ×(6Æ÷) 2373
68 ¸¶µ¥Ä«¼ÖÄɾ°í 6g 3242
69 ¸¶±×ºñ¸Æ½º¿¬Áúĸ½¶ 350
70 ¾ÈƼǪ¶ó¹Î ´õºíÆÄ¿ö ÁßÇü 2449
71 ÄÝ´ë¿øÅ°Áî³ëÁî¿¡½º½Ã·´ 3582
72 ŸÀÌ·¹³î8½Ã°£À̾˼­¹æÁ¤ 4028
73 ´ºº£ÀÎ¾× 664
74 ¾Ë·¯¼¦¿¬Áúĸ½¶ 4001
75 ´ÏÄÚ·¹Æ®²­ 2mg (Äð¹ÎÆ®Çâ) 808
76 ·ÎÅ侾ťºê ¾ÆÄí¾ÆÂ÷Áö12ml 2437
77 ¸ñ¾Ø½ºÇÁ·¹ÀÌ 1538
78 Á¶¾ÆÆË(10¸Å) 2033
79 ¸¶±×ºñ½ºÇÇµå ´õºí¾×¼Ç 1052
80 ·Î°ÔÀÎÆû60g(3°³) 180
81 Àλ絹Á¤(100Á¤) 507
82 Ä¡¼¾Ä¸½¶(120ĸ½¶) 308
83 ¶ó¶ó¿Ã¶ó¾× 20mL 1457
84 Ŭ¸®¾îƾ 1174
85 ´ë¿õ¿ì·ç»ç¿¬Áúĸ½¶(120ĸ½¶) 374
86 ¼¼ºñŸºñ°Ö 1139
87 Ä¡¼¾Ä¸½¶(60ĸ½¶) 521
88 ºñÆÇÅÙ¿¬°í 100g 512
89 ¼¾½Ã¾Æ(180Á¤) 195
90 ʼ¾·¹À̵ð¿¬Áúĸ½¶ 3244
91 µðÆæÄðÇöó½ºÅ¸(10¸Å) 2307
92 Ä«¸®ÅäÆ÷ÅÙ¿¬Áúĸ½¶(100ĸ½¶) 224
93 Àλ絹Ç÷¯½ºÁ¤(270Á¤) 182
94 èÇÁ½Ã·´ 2349
95 ¼ÒÇÏÀÚÀÓÇ÷¯½ºÁ¤ 3873
96 Å©¸°Å¬¸ê±Õ»ý¸®½Ä¿°¼ö20ml*20¾ÚÇà 1314
97 ÀÌÁö¿£6ÇÁ·Î¿¬Áúĸ½¶(30ĸ½¶) 1585
98 ¼¾½Ã¾ÆÁ¤(120Á¤) 248
99 ºñ¸Æ½º¸ÞŸÁ¤ 280
100 ¿ø±¤¿ìȲû½É¿øÇöʾ×50ml(»çÇâ,º¯¹æ) 686
Àüüº¸±â

ÀÎÅͳݽŹ®µî·Ï¹øÈ£: ¼­¿ï,¾Æ52715 | µî·ÏÀÏÀÚ 2019.11.20 | ¹ßÇàÀÏÀÚ 2019.11.20 | ¹ßÇàÀÎ : ÀÌÁ¤¼® | ÆíÁýÀÎ : °¡ÀÎÈ£
¹ßÇàÁÖ¼Ò: ¼­¿ï½Ã ¼ÛÆÄ±¸ ¹ý¿ø·Î 128 ¹®Á¤ SK V1 GL ¸ÞÆ®·Î½ÃƼ Aµ¿ 401È£
ÀüÈ­ : 02-3473-0833 |ÆÑ½º : 02-3474-0169 | û¼Ò³âº¸È£Á¤Ã¥(Ã¥ÀÓÀÚ °­½Å±¹)
Contact dailypharm@dailypharm.com for more information
µ¥Àϸ®ÆÊÀÇ ¸ðµç ÄÜÅÙÃ÷(±â»ç)¸¦ ¹«´Ü »ç¿ëÇÏ´Â °ÍÀº ÀúÀ۱ǹý¿¡ ÀúÃ˵Ǹç, ¹ýÀû Á¦À縦 ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù.